ENvue Medical, Inc.
FEEDNasdaq
$0.42
↓ -4.3%Jul 17 close · end-of-day
Price
1Y↓ -95.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.4M
Enterprise Value
-$867,084.52
P/E
—
P/S
0.6
P/B
0.0
EV/EBITDA
—
PEG
—
FCF Yield
-907.4%
Dividend Yield
—
Revenue (TTM)
$2.2M
Net Income (TTM)
-$20.1M
Free Cash Flow (TTM)
-$12.4M
Gross Margin
-12.4%
Operating Margin
-1134.7%
Net Margin
-923.2%
ROE
-62.9%
ROIC
-65.6%
Debt / Equity
—
Net Cash
$2.2M
Return 1Y
-95.9%
Company profile
NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low-intensity, surface acoustic wave technology. ... NanoVibronix' catheter-based products include the UroShield™ and NG-Shield™ devices that are both CE mark certified.
- CEO
- Brian M. Murphy
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 20
- Headquarters
- Texas
- Website
- nanovibronix.com
Earnings
FEED Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$653,000.00↓ -36.3%
Diluted EPS-$6.88↓ -77.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $623,000.00 | $1.7M | $752,000.00 | $2.3M | $2.6M | $2.6M |
| Gross profit | $214,000.00 | $770,000.00 | $167,000.00 | $1.5M | $1.5M | $153,000.00 |
| Operating income | -$4.7M | -$5.7M | -$5.0M | -$3.4M | -$3.6M | -$22.9M |
| Net income | -$4.3M | -$14.3M | -$5.4M | -$3.7M | -$3.7M | -$18.2M |
| Diluted EPS | — | — | -$3.84 | -$23.32 | -$137.30 | -$26.69 |
| Operating cash flow | -$3.4M | -$4.4M | -$7.0M | -$3.6M | -$2.5M | -$9.4M |
| Free cash flow | -$3.4M | -$4.4M | -$7.0M | -$3.6M | -$2.5M | -$9.4M |
| Gross margin | 34.3% | 45.4% | 22.2% | 67.3% | 59.0% | 6.0% |
| Operating margin | -757.5% | -335.3% | -666.5% | -150.5% | -140.0% | -896.6% |
| Net margin | -694.4% | -842.6% | -724.5% | -162.5% | -144.8% | -712.3% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $817,000.00 | $376,000.00 | $444,000.00 | $1.0M | $494,000.00 | $722,000.00 | $312,000.00 | $653,000.00 |
| Gross profit | $428,000.00 | $133,000.00 | $283,000.00 | $369,000.00 | -$35,000.00 | $189,000.00 | -$370,000.00 | -$55,000.00 |
| Operating income | -$674,000.00 | -$970,000.00 | -$1.4M | -$1.9M | -$4.0M | -$2.2M | -$14.8M | -$3.7M |
| Net income | -$688,000.00 | -$998,000.00 | -$1.4M | -$1.9M | -$4.0M | $510,000.00 | -$12.9M | -$3.8M |
| Diluted EPS | -$27.18 | -$3.56 | -$108.94 | -$29.90 | -$1.03 | -$0.91 | $5.15 | -$6.88 |
| Operating cash flow | -$553,000.00 | -$836,000.00 | -$548,000.00 | -$1.3M | -$3.4M | -$2.0M | -$2.7M | -$4.3M |
| Free cash flow | -$555,000.00 | -$836,000.00 | -$548,000.00 | -$1.3M | -$3.4M | -$2.0M | -$2.7M | -$4.3M |
| Gross margin | 52.4% | 35.4% | 63.7% | 36.0% | -7.1% | 26.2% | -118.6% | -8.4% |
| Operating margin | -82.5% | -258.0% | -308.6% | -180.7% | -804.9% | -311.2% | -4748.1% | -568.3% |
| Net margin | -84.2% | -265.4% | -322.3% | -182.6% | -803.8% | 70.6% | -4119.2% | -585.3% |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.